Informations générales (source: ClinicalTrials.gov)
Treatment of Graves' Orbitopathy in Patients Failing Corticosteroid Therapy: Multicenter National Retrospective Study- Basedow
Observational
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts (Voir sur ClinicalTrials)
novembre 2024
décembre 2025
15 septembre 2025
Describe the progression of inflammatory orbitopathy and the biological progression of
patients receiving second-line treatment (immunosuppressants, radiotherapy, or
biotherapy).
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHNO DES QUINZE-VINGTS PARIS | Boris BIENVENU, DR | Contact (sur clinicalTrials) | |||
| HOPITAL FONDATION A. DE ROTHSCHILD | Clara BOUCHE, DR | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| CHU Caen Normandie COTE DE NACRE - 14000 - Caen - France | Jean Claude QUINTYN, DR | Contact (sur clinicalTrials) | |||
| CHU de Montpellier - 34295 - Montpellier - France | Yves-Marie PERS, PR | Contact (sur clinicalTrials) | |||
| CHU de Pontchaillou - 35000 - Rennes - France | Na'im BEN MILOUD, DR | Contact (sur clinicalTrials) | |||
| CHU Lyon - Hospices Civils de Lyon - 69002 - Lyon - France | Juliette ABEILLON, DR | Contact (sur clinicalTrials) | |||
| CHU Nîmes - 30900 - Nîmes - France | Olivier GOHIER, DR | Contact (sur clinicalTrials) | |||
| Hopital Civil / Nouvel Hopital Civil - 67000 - Strasbourg - France | Lauriana SOLECKI, DR | Contact (sur clinicalTrials) | |||
| Hopital Saint Joseph - 13285 - Marseille - France | Antoine POULER, DR | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Patients aged 18 and older with moderate to severe orbitopathy;
- Patients followed in endocrinology with the goal of achieving euthyroidism;
- Corticosteroid-resistant patients: patients who have received at least 3 weeks of
treatment with 500 mg weekly corticosteroid boluses and have not shown improvement
in the clinical activity score (CAS);
- Corticosteroid-dependent patients: relapse with a CAS of 3 or higher when decreasing
or stopping corticosteroid therapy;
- Patients with a CAS ≥ 3 or CAS <3 with moderate to severe orbitopathy (according to
EUGOGO);
- Patients treated with immunotherapy, biotherapy, or radiotherapy as second-line
treatment;
- Patients who are not opposed to the reuse of their health data.
- Patients aged 18 and older with moderate to severe orbitopathy;
- Patients followed in endocrinology with the goal of achieving euthyroidism;
- Corticosteroid-resistant patients: patients who have received at least 3 weeks of
treatment with 500 mg weekly corticosteroid boluses and have not shown improvement
in the clinical activity score (CAS);
- Corticosteroid-dependent patients: relapse with a CAS of 3 or higher when decreasing
or stopping corticosteroid therapy;
- Patients with a CAS ≥ 3 or CAS <3 with moderate to severe orbitopathy (according to
EUGOGO);
- Patients treated with immunotherapy, biotherapy, or radiotherapy as second-line
treatment;
- Patients who are not opposed to the reuse of their health data.
- Patients who have undergone bone or fat decompression surgery;
- Patients with severe corneal involvement (Grade B or C; NO SPECS classification);
- Patients with optic neuropathy (Grade B and C; NO SPECS classification);
- Patients who have received 1 gram corticosteroid boluses for dysthyroid orbitopathy;
- Patients who have opposed the reuse of their health data.